B.S. (Environmental Science); U. of Massachusetts, Amherst, MA; 1997
M.D. (Medicine); U. of Massachusetts Medical School, Worcester, MA; 2007
Internship & Residency (Internal Medicine); New York University School of Medicine, New York, NY; 2010
Chief Residency (Medicine); Memorial Sloan-Kettering Cancer Center, New York, NY; 2011
Fellowship (Hematology and Oncology); University of Washington School of Medicine, Seattle, WA; 2014
As a medical oncologist and hematologist, Dr. Egan’s clinical expertise is in the diagnosis and management of benign and malignant hematologic disorders as well as solid tumors. He particularly specializes in the use autologous or allogeneic hematopoietic stem cell transplantation (HSCT) to treat patients with hematologic disorders.
Dr. Egan has studied the relationships between aspects of cancer biology, including genetic underpinnings, and cancer severity, in order to develop diagnostic/prognostic tests that can help identify optimal therapies for individual patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other hematologic malignancies.
He is actively focused on developing immune-based approaches to prevent and treat relapse of myeloid cancers, including after allogeneic HSCT. He is conducting a retrospective study of clinical and biologic factors that may determine responses to donor lymphocyte infusions in patients with post-transplant relapse of AML. He is also conducting a clinical trial of genetically engineered immune T cells for treating and/or preventing relapse of AML, CML or myelodysplastic syndromes (MDS) in patients who undergo allogeneic HSCT for these diseases.
Dr. Egan is Principle Investigator on a clinical trial that is investigating whether immune T cells engineered to express a WT1 antigen-specific T-cell receptor are effective at treating or preventing relapse of AML, MDS or CML in an allogeneic transplant population. The trial is open and enrolling: Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant.
Clinical and correlative laboratory studies are ongoing. Dr. Egan and colleagues are also developing a similar clinical trial that will investigate the safety and efficacy of WT1-specific effector memory and naïve T-cell populations in AML patients who do not undergo HSCT.